1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

Abbott Advances Transcath Mitral Valve Efforts With Cephea Acquisition

 
• By Catherine Longworth

Abbott has exercised an option to buy Cephea Valve Technologies, developer of a minimally-invasive replacement heart valve, for an undisclosed sum.

Mitral valve

Abbott Laboratories Inc. took another step to compete in the transcatheter mitral valve space by exercising its option to buy privately held Cephea Valve Technologies Inc. in full. Financial terms of the deal were not disclosed.

The California-based company is the developer of a minimally invasive heart valve replacement technology. Cephea’s artificial valve is designed to be delivered through a vein in the leg, sparing patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

More from Device Area

Pathogen Sharing System Part Of Global Pandemic Agreement

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.